Elspar
(Asparaginase)Phase 3Protein / enzyme
Asparaginase is used to treat certain types of leukemia and lymphoma by blocking a nutrient that cancer cells need to survive and grow.[1] Elspar is currently being investigated across 18 indications[3], with its most advanced program in Phase 3.[1]
Elspar is one of 398 small molecule programs targeting Childhood Acute Lymphoblastic Leukemia. It is currently in Phase 3.
18
Indications
87
Total Trials
13
Active Trials
397
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 18 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Elspar
DDutch Childhood Oncology Group
Phase 3
Oncaspar
SServier
Preclinical
Velban
EEastern Cooperative Oncology Group
Preclinical
Zofran
NovartisPreclinical
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
PEG-Intron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia47 trials
Show 44 more trials
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Completed·—·Phase 2·NCT00136435·100 enrolled
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Recruiting·—·Phase 2·NCT06918431·53 enrolled
Treatment of Acute Lymphoblastic Leukemia in Children
Completed·—·Phase 3·NCT00165178·498 enrolled
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Completed·—·Phase 3·NCT00400946·800 enrolled
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
Leukemia7 trials
Acute Myeloid Leukemia4 trials
B-cell acute lymphoblastic leukemia3 trials
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
Not yet recruiting·—·Phase 1·NCT07133997·26 enrolled
17 more indications
Lymphoblastic Lymphoma3 trials
Bone Marrow Transplantation3 trials
Acute Lymphoblastic Leukaemia2 trials
The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008
Completed·—··NCT04187248·1,248 enrolled
Myelodysplastic Syndromes2 trials
Hypersensitivity1 trial
Newly Diagnosed1 trial
Treatment1 trial
Allergy1 trial
Myelodysplastic Syndrome1 trial
Myeloproliferative Disorder1 trial
Nasopharyngeal Carcinoma1 trial
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
Completed·—·N/A·NCT06676293·8 enrolled
Childhood Acute Lymphoblastic Leukemia1 trial
Treatment of Childhood Acute Lymphoblastic Leukemia
Terminated·—·Phase 3·NCT00165087·491 enrolled
B Acute Lymphoblastic Leukemia1 trial
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Asparaginase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- DDutch Childhood Oncology Group